Fortress Biotech Stock Quote FBIO - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

1.75

Bid

1.75

Ask

1.83

Volume

111,437

1.72 Day's Range 1.82

1.24 52 Week Range 10.35

Market Cap

35.052M

Previous Close

1.76

Open

1.72

Last Trade

924

1.75

(formt)

Last Trade Time

18:09:31

Financial Volume

$ 195,429

VWAP

1.7537

Average Volume (3m)

179,660

Shares Outstanding

19,916,124

Dividend Yield

PE Ratio

-0.52

Earnings Per Share (EPS)

-3.45

Revenue

84.51M

Net Profit

-68.67M

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the g... Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.fortressbiotech.com

Headquarters

Dover, Delaware, USA

Founded

1970

Fortress Biotech Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker FBIO. The last closing price for Fortress Biotech was $1.76. Over the last year, Fortress Biotech shares have traded in a share price range of $ 1.24 to $ 10.35.

Fortress Biotech currently has 19,916,124 shares outstanding. The market capitalization of Fortress Biotech is $35.05 million. Fortress Biotech has a price to earnings ratio (PE ratio) of -0.52.

Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

MIAMI, July 05, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO; FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance...

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

WORCESTER, Mass., June 21, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s...

Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization...

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

WORCESTER, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s...

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months All patients were heavily pretreated/refractory to BTK inhibitors...

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.08	4.79041916168	1.67	1.85	1.62	139158	1.71617937	CS
4	-0.0612	-3.37897526502	1.8112	2.05	1.6	216135	1.82066047	CS
12	-0.08	-4.37158469945	1.83	2.0697	1.6	179660	1.80812736	CS
26	-0.73	-29.435483871	2.48	2.615	1.6	289379	1.9374981	CS
52	-6.95	-79.8850574713	8.7	10.35	1.24	470566	3.86923742	CS
156	-51.35	-96.7043314501	53.1	57.15	1.24	494229	16.59599813	CS
260	-21.35	-92.4242424242	23.1	91.5	1.24	641103	35.58239191	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
DYNTDynatronics Corp	$ 0.3251 (53.35%)	5.64M
SHPWShapeways Holdings Inc	$ 0.30 (42.86%)	2.08M
IDYAIDEAYA Biosciences Inc	$ 40.75 (18.94%)	55.44k
LGHLWLion Group Holding Ltd	$ 0.009 (15.38%)	37.68k
ABIOARCA Biopharma Inc	$ 3.9048 (13.51%)	1.14k
ABTSAbits Group Ltd	$ 0.40 (-16.95%)	22.86k
GTBPGT Biopharma Inc	$ 2.65 (-7.99%)	2k
ZCARZoomcar Holdings Inc	$ 0.1731 (-7.97%)	218.97k
AHGAkso Health Group	$ 1.05 (-7.89%)	11.1k
SMXSMX Security Matters Public Company	$ 0.125 (-7.41%)	1.42M
MAXNMaxeon Solar Technologies Ltd	$ 0.243 (1.25%)	24.3M
WBDWarner Brothers Discovery Inc	$ 7.21 (0.00%)	6.16M
DYNTDynatronics Corp	$ 0.3251 (53.35%)	5.64M
NVDANVIDIA Corporation	$ 125.5999 (-0.18%)	4.72M
SBUXStarbucks Corporation	$ 76.0099 (-0.05%)	3.07M